**Name of journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 32908**

**Manuscript Type: EDITORIAL**

**Can a fibrotic liver afford epithelial-mesenchymal transition?**

Munker S *et al.* Epithelial-mesenchymal transition in liver fibrosis

Stefan Munker, Yong-Le Wu, Hui-Guo Ding, Roman Liebe, Hong-Lei Weng

**Stefan Munker, Roman Liebe, Hong-Lei Weng,** Department of Medicine II, Section Molecular Hepatology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany

**Stefan Munker,** Department of Medicine I, University Medical Center, Regensburg University, 93053 Regensburg, Germany

**Yong-Le Wu, Hui-Guo Ding,** Department of Gastroenterology and Hepatology, Beijing You’an Hospital affiliated to Capital Medical University, Beijing 100069, China

**Hui-Guo Ding,** Major infectious diseases Collaborative Innovation Center, Beijing 100069, China

**Roman Liebe,** Department of Medicine II, Saarland University Medical Center, Saarland University, 66123 Homburg, Germany

**Author contributions:** Weng HL conceived and designed the manuscript; Munker S, Wu YL, Ding HG, Liebe R and Weng HL wrote and edited the manuscript.

**Supported by:** Munker S, Weng HL were supported by Chinese-German Cooperation Group project, No. GZ 1263; Ding HG was supported by the National Science Fund, No. 81672725; the Capital Science and Technology Development Fund, No. 2014-1-2181; and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding, No. ZYLX201610.

**Conflict-of-interest** **statement:** No potential conflicts of interest relevant to this article were reported.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Hong-Lei Weng, PhD, Principle Investigator,** Department of Medicine II, Section Molecular Hepatology, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany. honglei.weng@medma.uni-heidelberg.de

**Telephone**: +49-621-3835603

**Fax**: +49-621-3831467

**Received:** Janaury 25, 2017

**Peer-review started:** February 1, 2017

**First decision:** March 20, 2017

**Revised:** April 4, 2017

**Accepted:** May 19, 2017

**Article in press:**

**Published online:**

**Abstract**

The question whether epithelial-mesenchymal transition (EMT) occurs during liver fibrogenesis is a controversial issue. *In vitro* studies confirm that hepatocytes or cholangiocytes undergo EMT upon transforming growth factor β (TGF-) stimulation, whereas *in vivo* experiments based on genetic fate mapping of specific cell populations suggest that EMT does not occur in fibrotic animal models. In this review we present current data supporting or opposing EMT in chronic liver disease and discuss conditions for the occurrence of EMT in patients. Based on the available data and our clinical observations we hypothesize that EMT-like alterations in liver cirrhosis are a side effect of high levels of TGF- and other pro-fibrotic mediators rather than a biological process converting functional parenchyma, *i.e.,* hepatocytes, into myofibroblasts at a time when essential liver functions are deteriorating.

**Key words:** Epithelial-mesenchymal transition; Liver fibrosis; Liver cirrhosis; TGF-β

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This review provides a personal notion about whether a complete epithelial-mesenchymal transition (EMT) occurs in human fibrotic livers. We consider three aspects that might determine the occurrence of EMT: (1) capacity of parenchymal cells; (2) potential benefit for the liver and the whole body; and (3) microenvironment within a fibrotic liver. Clinical evidence suggests that in humans, EMT-like alterations occur mainly in advanced chronic liver disease, *i.e.,* cirrhosis. In such a severe disease state, the most urgent mission for a liver is to maintain a maximum number of functional hepatocytes, while hepatic stellate cells and portal fibroblasts provide an ample supply of myofibroblasts. It appears that there is no need for additional sources of myofibroblasts in a cirrhotic liver. EMT-like alterations in parenchymal cells are most likely a side effect of high levels of EMT-promoting factors such as TGF-β.

Munker S, Wu YL, Ding HG, Liebe R, Weng HL. Can a fibrotic liver afford epithelial-mesenchymal transition?*World J Gastroenterol* 2017; In press

**INTRODUCTION**

The progression of liver fibrosis is a dynamic process characterized by excessive deposition of extracellular matrix (ECM). Myofibroblasts (MFB) are the major ECM-producing cells[[1](#_ENREF_1),[2](#_ENREF_2)]. MFB are derived from different cell types with sinusoidal hepatic stellate cells (HSC), portal fibroblasts and bone marrow-derived fibrocytes being the most prominent sources[[3](#_ENREF_3)]. Whether hepatocytes and/or cholangiocytes differentiate into MFB by way of epithelial-to-mesenchymal transition (EMT) is still controversial[[4-10](#_ENREF_3)]. In this review, we discuss actual data supporting or opposing the occurrence of EMT during liver fibrogenesis.

***Why does EMT occur during embryogenesis?***

A hypothetical biological process requires three preconditions: (1) the process has to provide a benefit to either the local organ or the system; (2) the cells must be capable of performing the process; and (3) the process must be supported by the surrounding microenvironment. EMT is classified into three subtypes[[11](#_ENREF_3)]: Type 1 EMT, which is associated with implantation, embryo formation, and organ development; type 2 EMT, which is a repair-associated function that generates fibroblasts and other related cells in order to reconstruct tissues following trauma and inflammatory injury; and type 3 EMT in neoplastic cells that have previously undergone genetic and epigenetic changes, particularly in genes that favor clonal outgrowth and the dissemination of tumors. So far, type 1 EMT is the best-characterized subclass, occuring in the embryo at gastrulation[12,13]. A subset of cells from the epiblast moves to the midline to form the primitive streak. These cells undergo EMT and internalize to generate mesoderm and endoderm, while those remaining in the epiblast become ectoderm[12,13]. EMT and MET between endoderm and mesoderm are critical mechanisms for organogenesis, for example in the kidney[14-16]. However, EMT does not play an important role during liver organogenesis because hepatoblasts, from which hepatocytes and BEC are subsequently derived, arise from endoderm rather than mesoderm[17].

**EVIDENCE SUPPORTING AND OPPOSING EMT IN LIVER FIBROSIS**

According to a brief definition of EMT, that is, “epithelial cells changing their phenotype and acquiring mesenchymal properties” [11], two types of adult liver cells can undergo EMT under experimental conditions: hepatocytes and cholangiocytes[18]. Given that HSC are mesenchymal cell in the first place, regardless if quiescent or activated, the conversion of HSC into MFB is not considered EMT. Thus the term EMT refers to the process of hepatocytes or cholangiocytes obtaining phenotypes of mesenchymal cells and differentiating into MFB.

***Parenchymal cells express mesenchymal markers in patients with advanced chronic liver disease***

Evidence supporting the occurrence of EMT during liver fibrogenesis is based on immunohistochemistry and co-staining studies. Expression of multiple mesenchymal markers, including vimentin, S100A4 (fibroblast-specific protein, FSP-1), heat shock protein 47 (HSP47), snail, and α-smooth muscle actin (α-SMA), has been reported in parenchymal cells of patients with different chronic liver disease[17,19,22]. AM Diehl’s group showed that S100A4 is expressed in reactive ducts of patients with primary biliary cholangitis (PBC) and of cirrhotic patients with non-alcoholic steatohepatitis (NASH)[19,21]. Diaz *et al*[17] found that in pediatric patients with biliary atresia and adult patients with primary sclerosing cholangitis (PSC)/PBC, cholangiocytes and reactive ducts express FSP-1, the collagen chaperone HSP47, the intermediate filament protein vimentin, and the transcription factor snail. Dooley *et al*[20] showed that a portion of hepatocytes in patients with HBV-associated cirrhosis expressed Snail. These results suggest that parenchymal cells do indeed express mesenchymal markers in chronic liver disease. It should be noted that parenchymal cells expressing mesenchymal markers have only been found in patients with advanced chronic liver disease, *e.g.,* cirrhosis so far. There is no data showing that parenchymal cells of patients express mesenchymal markers at early stages of liver fibrosis.

***In vitro studies confirm the occurrence of EMT in liver cells***

Further evidence supporting the occurrence of EMT of liver parenchymal cells comes from *in vitro* studies. Fetal rat hepatocytes treated with transforming growth factor β (TGF-β) underwent an EMT, presenting high levels of vimentin and Snail and lack of cytokeratin 18 and E-cadherin[23]. Murine primary hepatocytes cultured on monolayers of dry collagen undergo dedifferentiation and lose polarity and liver function within 3 d[24]. Changing culture conditions by seeding hepatocytes within a sandwich of two soft collagen gel layers preserves an epithelial phenotype for extended periods[24]. Upon TGF-β stimulation, primary hepatocytes on both dry collagen monolayer and soft collagen gel sandwich quickly exhibit myofibroblast-like morphological changes, lose tight junction proteins (*e.g.,* Occludin and E-cadherin), and express mesenchymal markers (vimentin, connective tissue growth factor, S100A4, *et al*)[4,24,25]. In contrast to hepatocytes of untreated mouse livers, hepatocytes derived from carbon tetrachloride (CCl4)-induced cirrhotic mice express vimentin, a mesenchymal marker, *in vitro* and *in vivo*[25].

TGF-β induces hepatocytes’ EMT through regulating the expression of transcription factors, in particular Snail, the master gene of EMT, and hepatocyte nuclear factor 4α (HNF4α), the master gene of hepatocyte differentiation[26,27]. The Snail family induces EMT in different epithelial cells, including hepatocytes. In fetal liver, TGF-β induces apoptosis of hepatocytes. Snail confers hepatocytes resistance to TGF-β-induced cell death[26,27]. In addition, Snail expression is sufficient to induce EMT in adult hepatocytes. HNF4α is an essential transcription factor maintaining the epithelial phenotype of hepatocytes[28]. During EMT of hepatocytes, expression of HNF4α is largely inhibited by TGF-β administration[27]. The inhibitory effects are performed by upregulating Snail, which represses transcription of the HNF4α gene through direct binding to its promoter[27]. The balance between these two transcription factors plays a pivotal role in regulating EMT/MET dynamics in hepatocytes[29].

Besides hepatocytes, primary cholangiocytes isolated from rats following one week of bile duct ligation (BDL) express S100A4 while showing reduced expression levels of epithelial markers such as cytokeratin 19 and 7[21]. When an immature cholangiocyte line was treated with conditioned medium from myofibroblastic HSC, these cholangiocytes underwent complete EMT[21]. Consistent with the findings in rat cholangiocytes, Rygiel *et al*[30] reported that administration of TGF-β induced expression of mesenchymal markers in cultured primary human cholangiocytes. These results show that (1) *in vitro* cell culture conditions (*e.g.,* putting cells on monolayer gel) induce hepatocytes’ loss of epithelial feature; and (2) pro-EMT factors in cultured medium, such as TGF-β, induce rapid EMT of liver parenchymal cells.

***Current fibrotic animal models deny the occurrence of EMT during liver fibrogenesis***

Although a study of the CCl4–induced fibrotic mouse model stated the occurrence of EMT during liver fibrosis[31], later studies based on genetic cell fate mapping provided convincing evidence that in contrast to liver parenchymal cells in primary culture, EMT does not occur in fibrotic animal models induced by BDL, CCl4, and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)[4,5,10]. This issue has been discussed intensively[3,6,8].

**TGF-β: BETWEEN FIBROSIS AND EMT**

As mentioned above, one key finding supporting the occurrence of EMT in damaged liver is that parenchymal cells express mesenchymal markers. Why would they do that? One explanation might be that there are high levels of growth factors such as TGF-β surrounding these cells.

TGF-β is not only the most important pro-fibrotic cytokine[32], but also the most efficient growth factor promoting EMT[33]. It has been confirmed that liver parenchymal cells undergo EMT in culture medium with TGF-β stimulation[4,24,25]. During chronic liver diseases, TGF-β is produced by multiple systemic and local cells, including macrophages, monocytes, activated HSC and reactive ducts[34,35]. In addition, TGF-β treatment also induces BMOL cells, a murine LPC line, to undergo EMT-like phenotype change *in vitro* (unpublished data). There is a close correlation between phosphorylated Smad2 levels and fibrotic stages in HBV- and steatosis-associated chronic liver disease[36]. This means that parenchymal cells in cirrhotic livers often reside in an environment teeming with high levels of TGF-β. It is quite likely that such a microenvironment can force the expression of mesenchymal markers in parenchymal cells.

However, the occurrence of EMT should not be defined merely by parenchymal cells expressing mesenchymal markers. To accomplish a complete EMT in the liver, hepatocytes or cholangiocytes are required to finish at least the following steps: (1) Expression of mesenchymal markers; (2) Loss of anchoring proteins such as E-cadherin and Occludin; and (3) Release from adjoined hepatocytes/cholangiocytes and conversion into an isolated MFB. To date, there is no conclusive evidence that hepatocytes or cholangiocytes expressing mesenchymal markers undergo the latter two steps and become real MFB.

It should be re-emphasized that parenchymal cells expressing mesenchymal markers are found only in advanced stages of chronic liver disease, particularly in cirrhosis. At this stage, survival of parenchymal cells for the maintenance of liver function is of prime importance. Therefore we surmise that the most likely scenario is that expression of mesenchymal markers parenchymal cells represents a response to high levels of TGF-β rather than evidence for EMT in a liver with severely impaired functions.

**CAN LIVERS EVEN AFFORD EMT IN CIRRHOTIC PATIENTS?**

Based on current data, it is too early to conclude that EMT of liver parenchymal cells contributes to the MFB pool *in vivo*. Given the vast difference between tissue culture and the human liver, observations of EMT following TGF-β incubation *in vitro* by no means provide convincing evidence that the same phenotypic alterations occur during progression of chronic liver disease *in vivo*. On the other hand, the fact that EMT does not occur in fibrotic animal models does not rule out the possibility of EMT in patients with chronic liver disease. The currently used fibrotic models have a maximum observation period of several months, whereas the history of a patient progressing to liver cirrhosis spans years and decades[37]. The fact that patients with chronic liver disease have such a long natural history bears witness to the huge capacity of the human liver for self-repair, even under continuous attack.

The liver is the largest gland in the body, and it supports nearly every other organ in some aspect. The majority of physiological functions of the liver are performed by hepatocytes, including metabolism of carbohydrates, proteins, amino acids, lipids and some important hormones, the production and excretion of bile, metabolism and excretion of toxic substances, and synthesis of coagulation factors[38]. In order to implement these copious complex physiological functions, the liver owns special blood systems and anatomic architecture. A hepatocyte has three boundaries: the sinusoidal, lateral and canalicular membranes[28]. The cell is highly polarized with transport directed from its sinusoidal surface to the canalicular surface[28]. The canalicular domains between two adjacent hepatocytes constitute the smallest bile lumen (diameter: 1 μm)[39]. The adjoining apical membranes of a bile lumen are sealed by tight junctions (zonula occludens), representing the only physical barrier between the blood and the canalicular lumen. These tight junctions determine “paracellular permeabilty” between blood and bile[39]. In normal liver, hepatocytes are arranged in one-cell thick cords[40]. Such arrangement makes hepatocyte-produced bile delivery easy. If a complete EMT should occur in these hepatocytes, one key issue would be that the loss of hepatocytes from these one-cell thick cords must not alter primary liver architecture. In a patient with chronic liver disease, the organ is under continuous insult and yet manages to maintain a normal function to support the body’s physiological requirements for several decades. To achieve this feat, the liver has to avoid any response that is likely to disturb the abovementioned hepatocyte arrangement.

Deposition of ECM by MFB is a key process in liver repair. In acute liver injury, particularly during acute liver failure, the severely damaged organ recruits enormous numbers of ECM-producing MFB in order to maintain a relatively intact liver architecture[41]. Furthermore, MFB and the ECM they produce are providing a niche for the activation of liver progenitor cells (LPC), a major cell source for liver regeneration in acute liver failure[42,43]. Under these conditions, most mature hepatocytes have gone extinct[44,45]. Still these copious amounts of MFB do not cause fibrosis: Once the damaging etiology is removed, the damaged liver can recover its function and restore its architecture completely, although fibrotic septa produced by MFB persist for several months or years. This process is summarized as “wound healing”.

In chronic liver disease, enduring damage induces excessive ECM deposition beyond the liver’s capacity for degradation[46]. Such excessive ECM deposition combined with local hepatocyte death and regeneration finally results in distortion of the hepatic architecture and vascular structures[47]. The process is described as liver fibrosis and its end stage cirrhosis. Actually, the line between “wound healing” and “fibrosis” is a blurred one. Defining the two processes only according to disease time, for example acute or chronic, is artificial. It is impossible to claim that ECM deposition in the liver during chronic disease is completely “fibrogenesis”, rather than “wound healing”. During several decades of chronic liver disease progression, the human body is constantly trying to repair and restore the damaged liver. Before decompensated liver cirrhosis is established, withdrawal of etiology can still reverse liver fibrosis and even cirrhosis to some degree[48,49]. Regeneration and repair represent two aspects of host defence. When we discuss whether EMT occurs in chronic liver damage or not, it is important to consider whether there is actually any requirement for hepatocytes to transdifferentiate into MFB through EMT. In our view, it is highly doubtful if MFB derived from other cell sources, *e.g.,* HSC, should be insufficient to produce the amount of ECM required for healing and repair.

Morphologically, at least five fibrotic septa patterns are demonstrated in patients with liver fibrosis: portal to portal, portal to central, central to central, chicken–wire and portal pipestem[40,50]. Etiology, the topographic localization and nature of injury, and disease stage are critical factors that determine the pattern of liver fibrosis.

Patients with alcoholic steatohepatitis (ASH) or NASH usually have pericellular fibrosis, *i.e.,* the deposition of fibrillar matrix is concentrated around the sinusoids and groups of hepatocytes and displays a chicken–wire like shape [40](#_ENREF_40), [50](#_ENREF_50). It is well recognized that this “chicken–wire fibrosis” is dependent on sinusoidal HSC activation. Do hepatocytes undergo EMT and transdifferentiate into MFB in these circumstances? Most likely not: In patients with ASH or NASH, hepatocytes manifest with steatosis, ballooning degeneration, and containing Mallory-Denk bodies. These cells usually do not have an intact liver function. Severe ASH or NASH leads to lytic necrosis and apoptosis of hepatocytes. In the end-stage of these diseases, particularly in ASH, there may be large amounts of parenchy­mal extinction, suggesting secondary vascular events[40]. Under these circumstances, the most important mission for surviving hepatocytes is maintaining liver function. It is difficult to fathom that such a liver would induce EMT in functionally impaired, or even in some of the few remaining functional hepatocytes. On the other hand, no data indicate that there might be insufficient HSC-derived MFBs to produce the amount of ECM required for tissue repair and/or fibrogenesis.

In contrast to ASH and NASH, ECM deposition in biliary disease is dependent on portal fibroblasts. In cholestatic diseases such as PBC and PSC, fibrosis initiates from portal tracts, induced by obstruction, loss, or inflammation of bile ducts[51]. Geographically, peribiliary fibroblast-derived MFB are primarily responsible for the deposition of portal tract collagen[52]. The biliary fibrosis due to activation of peribiliary and portal fibroblasts explains the lack of subdivision with parenchymal fibrotic septa until late stages of the disease[40]. Morphologically, the MFB of bridging septa in cholestatic livers strongly resemble the MFB of the portal field[53]. These cells can be distinguished from HSC-derived MFB using combined staining for fibrillin-1 and elastin[52]. Activated HSC generate fibrillin-1-positive but elastin-negative ECM, whereas MFB inside the portal tracts produce both fibrillin-1- and elastin-positive ECM[54]. In addition, activated portal tract fibroblasts express some different protein markers such as cellular retinol-binding protein-1 (CRBP-1) [55].

Besides activation of portal fibroblasts, ductular reaction (DR), which is defined as “ductules accompanied by an inflammatory infiltrate and by fibrosis”, is a critical histological feature in most cholestatic liver diseases[51,56-58]. It is mainly reactive ducts that have previously been reported to express mesenchymal markers[17,21]. Will these reactive ducts expressing mesenchymal markers differentiate into MFB? To date there is no evidence supporting this hypothesis. DR in cholestatic liver disease has several cell sources, including the small intralobular bile ducts, ductules, canals of Hering and from ‘ductular metaplasia’ of periportal hepatocytes[58]. Cholestatic pathogenesis is initiated by bile leakage due to obstruction of extrahepatic bile ducts and loss of small intrahepatic bile ducts. DR accompanied by inflammation and fibrosis constitutes a protective response to the destruction of interlobular bile ducts. These reactive ducts provide abortive bypass mechanisms for the drainage of bile in the diseased liver, and thus protect hepatocytes from the deleterious effect of bile acid overload[59]. It has been well recognized that LPC residing in canals of Hering are the major source of DR in cholestatic diseases[58]. In advanced stages of PSC, severe destruction of small ductules including canals of Hering reduces the number and size of DR[60]. Thus, it is clear that DR is a key process of the liver in order to restore the architecture of a damaged biliary tree. LPC are activated and undergo differentiation to cholangiocytes to recover ruined bile ducts. On the other hand, DR and the accompanying inflammatory response indeed play an important role in portal and periportal fibrosis by producing and secreting a variety of biologically active fibrosis-associated mediators, including TGF-β2, connective tissue growth factor, platelet derived growth factor, tumor necrosis factor-α, interleukin (IL)-6, IL-8, monocyte chemotactic protein-1 and nitric oxide[61]. Thus, these data suggest that DR contributes to biliary fibrosis through producing critical pro-fibrogenesis factors rather than differentiating into mesenchymal cells.

**HYPOTHESIS: HEPATOCYTES ARE NOT ALLOWED TO PERFORM EMT IN A CIRRHOTIC LIVER**

Human liver cirrhosis develops over years or decades. Histologically it is characterized by diffuse nodular regeneration surrounded by dense fibrotic septa with subsequent parenchymal extinction and collapse of liver structures, causing pronounced distortion of hepatic vascular architecture[40,47,62,63]. Of all these histological features, parenchymal extinction is rarely found in animal models[46]. Parenchymal extinction denotes the loss of contiguous hepatocytes, producing lesions that remodel into septa that vary from 0.05 mm to several millimeters in thickness[60,62]. Only recently, an elegant study from Stueck and Wanless showed that repopulation of parenchymal extinction lesions in cirrhotic human liver is dependent on LPC activation[60]. This result suggests that without LPC-derived hepatocytes, the remaining mature hepatocytes in a cirrhotic liver are not sufficient to ensure liver function. The most urgent mission of a cirrhotic liver is to maintain a maximum number of functional mature hepatocytes, either by proliferation of the remaining hepatocytes, or from LPC. Proliferating cells cannot perform EMT in breast cancer cells[64,65]. Consistent with breast cancer cells, TGF-β administration or overexpression of Snail induce EMT as well as cell cycle arrest, which favors survival signals in hepatocytes[27]. Thus, a cirrhotic liver is unlikely to support or induce a biological process like EMT in the surviving parenchymal cells. On the other hand, the decision if EMT is requires for hepatic fibrogenesis and tissue repair might also depend on whether MFB derived from other cell sources provide sufficient ECM. At the present time, there are no studies indicating that the activated HSC, portal fibroblasts and fibrocytes provide insufficient MFB.

**CONCLUSION**

It may be too early yet to exclude the occurrence of type 2 EMT in patients with chronic liver damage. However, current evidence indicates that EMT only occurs in the advanced stages of chronic liver disease. In this phase, *i.e.,* during cirrhosis, mature hepatocytes performing vital functions are decreasing in numbers. LPCs are activated to replenish hepatocytes in order to maintain crucial liver functions[[60](#_ENREF_60)]. Under these conditions, it seems rather counterproductive for a severely damaged liver to induce conversion of hepatocytes into MFB. There are multiple alternative sources of MFB, including HSC, portal fibroblasts and fibrocytes. To date, there is no evidence suggesting that these cell sources produce insufficient MFB for liver repair or fibrogenesis. We propose that in the cirrhotic liver, parenchymal cells express mesenchymal markers in response to high levels of surrounding pro-EMT factors, *e.g.*, TGF-β.

The notions discussed in this paper are based on our observations only, and at present lack supporting experimental evidence. We hope that future studies and observations will provide clinical evidence to confirm, correct or refute our hypothesis. Table 1 summarizes current evidence supporting or opposing EMT during liver fibrogenesis.

**REFERENCES**

1 **Bataller R**, Brenner DA. Liver fibrosis. *J Clin Invest* 2005; **115**: 209-218 [PMID: 15690074 DOI: 10.1172/JCI24282]

2 **Friedman SL**. Mechanisms of hepatic fibrogenesis. *Gastroenterology* 2008; **134**: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]

3 **Kisseleva T**, Brenner DA. Anti-fibrogenic strategies and the regression of fibrosis. *Best Pract Res Clin Gastroenterol* 2011; **25**: 305-317 [PMID: 21497747 DOI: 10.1016/j.bpg.2011.02.011]

4 **Taura K**, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M, Brenner DA. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. *Hepatology* 2010; **51**: 1027-1036 [PMID: 20052656 DOI: 10.1002/hep.23368]

5 **Scholten D**, Osterreicher CH, Scholten A, Iwaisako K, Gu G, Brenner DA, Kisseleva T. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. *Gastroenterology* 2010; **139**: 987-998 [PMID: 20546735 DOI: 10.1053/j.gastro.2010.05.005]

6 **Wells RG**. The epithelial-to-mesenchymal transition in liver fibrosis: here today, gone tomorrow? *Hepatology* 2010; **51**: 737-740 [PMID: 20198628 DOI: 10.1002/hep.23529]

7 **Popov Y**, Schuppan D. Epithelial-to-mesenchymal transition in liver fibrosis: dead or alive? *Gastroenterology* 2010; **139**: 722-725 [PMID: 20682361 DOI: 10.1053/j.gastro.2010.07.015]

8 **Pinzani M**. Epithelial-mesenchymal transition in chronic liver disease: fibrogenesis or escape from death? *J Hepatol* 2011; **55**: 459-465 [PMID: 21320559 DOI: 10.1016/j.jhep.2011.02.001]

9 **Kisseleva T**, Brenner DA. Is it the end of the line for the EMT? *Hepatology* 2011; **53**: 1433-1435 [PMID: 21433040 DOI: 10.1002/hep.24312]

10 **Chu AS**, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, Stanger BZ, Wells RG. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. *Hepatology* 2011; **53**: 1685-1695 [PMID: 21520179 DOI: 10.1002/hep.24206]

11 **Kalluri R**, Weinberg RA. The basics of epithelial-mesenchymal transition. *J Clin Invest* 2009; **119**: 1420-1428 [PMID: 19487818 DOI: 10.1172/JCI39104]

12 **Thiery JP**, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell* 2009; **139**: 871-890 [PMID: 19945376 DOI: 10.1016/j.cell.2009.11.007]

13 **Acloque H,** Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. *J Clin Invest* 2009; **119**:1438-49 [PMID: 19487820 DOI: 10.1172/JCI38019]

14 **Herzlinger D**. Renal interstitial fibrosis: remembrance of things past? J Clin Invest 2002; **110**: 305-306 [PMID: 12163448 DOI: 10.1172/JCI0216377]

15 **Tremblay KD**, Zaret KS. Distinct populations of endoderm cells converge to generate the embryonic liver bud and ventral foregut tissues. *Dev Biol* 2005; **280**: 87-99 [PMID: 15766750 DOI: 10.1016/j.ydbio.2005.01.003]

16 **Gu G**, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. *Development* 2002; **129**: 2447-2457 [PMID: 11973276]

17 **Díaz R**, Kim JW, Hui JJ, Li Z, Swain GP, Fong KS, Csiszar K, Russo PA, Rand EB, Furth EE, Wells RG. Evidence for the epithelial to mesenchymal transition in biliary atresia fibrosis. *Hum Pathol* 2008; **39**: 102-115 [PMID: 17900655 DOI: 10.1016/j.humpath.2007.05.021]

18 **Choi SS**, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. *Hepatology* 2009; **50**: 2007-2013 [PMID: 19824076 DOI: 10.1002/hep.23196]

19 **Syn WK**, Jung Y, Omenetti A, Abdelmalek M, Guy CD, Yang L, Wang J, Witek RP, Fearing CM, Pereira TA, Teaberry V, Choi SS, Conde-Vancells J, Karaca GF, Diehl AM. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. *Gastroenterology* 2009; **137**: 1478-1488.e8 [PMID: 19577569 DOI: 10.1053/j.gastro.2009.06.051]

20 **Dooley S**, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A, Breitkopf K, Weng H, Mertens PR. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. *Gastroenterology* 2008; **135**: 642-659 [PMID: 18602923 DOI: 10.1053/j.gastro.2008.04.038]

21 **Omenetti A**, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, Witek RP, Alpini G, Venter J, Vandongen HM, Syn WK, Baroni GS, Benedetti A, Schuppan D, Diehl AM. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. *J Clin Invest* 2008; **118**: 3331-3342 [PMID: 18802480 DOI: 10.1172/jci35875]

22 **Sicklick JK**, Choi SS, Bustamante M, McCall SJ, Pérez EH, Huang J, Li YX, Rojkind M, Diehl AM. Evidence for epithelial-mesenchymal transitions in adult liver cells. *Am J Physiol Gastrointest Liver Physiol* 2006; **291**: G575-G583 [PMID: 16710052 DOI: 10.1152/ajpgi.00102.2006]

23 **Valdés F**, Alvarez AM, Locascio A, Vega S, Herrera B, Fernández M, Benito M, Nieto MA, Fabregat I. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. *Mol Cancer Res* 2002; **1**: 68-78 [PMID: 12496370]

24 **Godoy P**, Hengstler JG, Ilkavets I, Meyer C, Bachmann A, Müller A, Tuschl G, Mueller SO, Dooley S. Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. *Hepatology* 2009; **49**: 2031-2043 [PMID: 19274752 DOI: 10.1002/hep.22880]

25 **Nitta T**, Kim JS, Mohuczy D, Behrns KE. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. *Hepatology* 2008; **48**: 909-919 [PMID: 18712785 DOI: 10.1002/hep.22397]

26 **Cicchini C**, Filippini D, Coen S, Marchetti A, Cavallari C, Laudadio I, Spagnoli FM, Alonzi T, Tripodi M. Snail controls differentiation of hepatocytes by repressing HNF4alpha expression. *J Cell Physiol* 2006; **209**: 230-238 [PMID: 16826572 DOI: 10.1002/jcp.20730]

27 **Franco DL**, Mainez J, Vega S, Sancho P, Murillo MM, de Frutos CA, Del Castillo G, López-Blau C, Fabregat I, Nieto MA. Snail1 suppresses TGF-beta-induced apoptosis and is sufficient to trigger EMT in hepatocytes. *J Cell Sci* 2010; **123**: 3467-3477 [PMID: 20930141 DOI: 10.1242/jcs.068692]

28 **Treyer A**, Musch A: Hepatocyte polarity. *Compr Physiol* 2013; **3:** 243-287 [DOI: 10.1002/cphy.c120009]

29 **Cicchini C**, Amicone L, Alonzi T, Marchetti A, Mancone C, Tripodi M. Molecular mechanisms controlling the phenotype and the EMT/MET dynamics of hepatocyte. *Liver Int* 2015; **35**: 302-310 [PMID: 24766136 DOI: 10.1111/liv.12577]

30 **Rygiel KA**, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, Jones DE, Burt AD, Kirby JA. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. *Lab Invest* 2008; **88**: 112-123 [PMID: 18059363 DOI: 10.1038/labinvest.3700704]

31 **Zeisberg M**, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Kalluri R. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. *J Biol Chem* 2007; **282**: 23337-23347 [PMID: 17562716 DOI: 10.1074/jbc.M700194200]

32 **Brenner DA**. Molecular pathogenesis of liver fibrosis. *Trans Am Clin Climatol Assoc* 2009; **120**: 361-368 [PMID: 19768189]

33 **Heldin CH**, Landström M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. *Curr Opin Cell Biol* 2009; **21**: 166-176 [PMID: 19237272 DOI: 10.1016/j.ceb.2009.01.021]

34 **Bissell DM**, Roulot D, George J. Transforming growth factor beta and the liver. *Hepatology* 2001; **34**: 859-867 [PMID: 11679955 DOI: 10.1053/jhep.2001.28457]

35 **Gressner AM**, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. *Front Biosci* 2002; **7**: d793-d807 [PMID: 11897555 DOI: 10.2741/A812]

36 **Weng HL**, Liu Y, Chen JL, Huang T, Xu LJ, Godoy P, Hu JH, Zhou C, Stickel F, Marx A, Bohle RM, Zimmer V, Lammert F, Mueller S, Gigou M, Samuel D, Mertens PR, Singer MV, Seitz HK, Dooley S. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. *Hepatology* 2009; **50**: 230-243 [PMID: 19441105 DOI: 10.1002/hep.22934]

37 **Pellicoro A**, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. *Nat Rev Immunol* 2014; **14**: 181-194 [PMID: 24566915 DOI: 10.1038/nri3623]

38 **Wallace K**, Burt AD, Wright MC. Liver fibrosis. *Biochem J* 2008; **411**: 1-18 [PMID: 18333835 DOI: 10.1042/BJ20071570]

39 **Boyer JL**. Bile formation and secretion. *Compr Physiol* 2013; **3**: 1035-1078 [PMID: 23897680 DOI: 10.1002/cphy.c120027]

40 **Alastair D.** Burt BCP, Linda D. Ferrel: MacSween's Pathology of the Liver, 6th ed. 6th ed, 2012.

41 **Dechêne A**, Sowa JP, Gieseler RK, Jochum C, Bechmann LP, El Fouly A, Schlattjan M, Saner F, Baba HA, Paul A, Dries V, Odenthal M, Gerken G, Friedman SL, Canbay A. Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. *Hepatology* 2010; **52**: 1008-1016 [PMID: 20684020 DOI: 10.1002/hep.23754]

42 **Lorenzini S**, Bird TG, Boulter L, Bellamy C, Samuel K, Aucott R, Clayton E, Andreone P, Bernardi M, Golding M, Alison MR, Iredale JP, Forbes SJ. Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. *Gut* 2010; **59**: 645-654 [PMID: 20427399 DOI: 10.1136/gut.2009.182345]

43 **Kallis YN**, Robson AJ, Fallowfield JA, Thomas HC, Alison MR, Wright NA, Goldin RD, Iredale JP, Forbes SJ. Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response. *Gut* 2011; **60**: 525-533 [PMID: 21106552 DOI: 10.1136/gut.2010.224436]

44 **Lucké B**. The Pathology of Fatal Epidemic Hepatitis. *Am J Pathol* 1944; **20**: 471-593 [PMID: 19970766]

45 **Lucke B**, Mallory T: The fulminant form of epidemic hepatitis. *Am J Pathol* 1946; **22**: 867-947

46 **Wynn TA**. Cellular and molecular mechanisms of fibrosis. *J Pathol* 2008; **214**: 199-210 [PMID: 18161745 DOI: 10.1002/path.2277]

47 **Schuppan D**, Afdhal NH. Liver cirrhosis. *Lancet* 2008; **371**: 838-851 [PMID: 18328931 DOI: 10.1016/S0140-6736(08)60383-9]

48 **Wanless IR**, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. *Arch Pathol Lab Med* 2000; **124**: 1599-1607 [PMID: 11079009]

49 **Hytiroglou P**, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Nakanuma Y, Paradis V, Quaglia A, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ. Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. *Am J Clin Pathol* 2012; **137**: 5-9 [PMID: 22180471 DOI: 10.1309/AJCP2T2OHTAPBTMP]

50 **Pinzani M**, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. *J Hepatol* 2005; **42** Suppl: S22-S36 [PMID: 15777570 DOI: 10.1016/j.jhep.2004.12.008]

51 **Roskams TA**, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, Brunt EM, Crawford JM, Crosby HA, Desmet V, Finegold MJ, Geller SA, Gouw AS, Hytiroglou P, Knisely AS, Kojiro M, Lefkowitch JH, Nakanuma Y, Olynyk JK, Park YN, Portmann B, Saxena R, Scheuer PJ, Strain AJ, Thung SN, Wanless IR, West AB. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. *Hepatology* 2004; **39**: 1739-1745 [PMID: 15185318 DOI: 10.1002/hep.20130]

52 **Penz-Österreicher M**, Österreicher CH, Trauner M. Fibrosis in autoimmune and cholestatic liver disease. *Best Pract Res Clin Gastroenterol* 2011; **25**: 245-258 [PMID: 21497742 DOI: 10.1016/j.bpg.2011.02.001]

53 **Cassiman D**, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. *J Hepatol* 2002; **36**: 200-209 [PMID: 11830331 DOI: 10.1016/S0168-8278(01)00260-4]

54 **Lamireau T**, Dubuisson L, Lepreux S, Bioulac-Sage P, Fabre M, Rosenbaum J, Desmoulière A. Abnormal hepatic expression of fibrillin-1 in children with cholestasis. *Am J Surg Pathol* 2002; **26**: 637-646 [PMID: 11979094 DOI: 10.1097/00000478-200205000-00010]

55 **Wells RG**. The portal fibroblast: not just a poor man's stellate cell. *Gastroenterology* 2014; **147**: 41-47 [PMID: 24814904 DOI: 10.1053/j.gastro.2014.05.001]

56 **Desmet VJ**. Ductal plates in hepatic ductular reactions. Hypothesis and implications. III. Implications for liver pathology. *Virchows Arch* 2011; **458**: 271-279 [PMID: 21301864 DOI: 10.1007/s00428-011-1050-9]

57 **Desmet VJ**. Ductal plates in hepatic ductular reactions. Hypothesis and implications. II. Ontogenic liver growth in childhood. *Virchows Arch* 2011; **458**: 261-270 [PMID: 21298286 DOI: 10.1007/s00428-011-1049-2]

58 **Desmet VJ**. Ductal plates in hepatic ductular reactions. Hypothesis and implications. I. Types of ductular reaction reconsidered. *Virchows Arch* 2011; **458**: 251-259 [PMID: 21287200 DOI: 10.1007/s00428-011-1048-3]

59 **Yamada S**, Howe S, Scheuer PJ. Three-dimensional reconstruction of biliary pathways in primary biliary cirrhosis: a computer-assisted study. *J Pathol* 1987; **152**: 317-323 [PMID: 3668734 DOI: 10.1002/path.1711520410]

60 **Stueck AE**, Wanless IR. Hepatocyte buds derived from progenitor cells repopulate regions of parenchymal extinction in human cirrhosis. *Hepatology* 2015; **61**: 1696-1707 [PMID: 25644399 DOI: 10.1002/hep.27706]

61 **Strazzabosco M**, Fabris L. Development of the bile ducts: essentials for the clinical hepatologist. *J Hepatol* 2012; **56**: 1159-1170 [PMID: 22245898 DOI: 10.1016/j.jhep.2011.09.022]

62 **Wanless IR**, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. *Hepatology* 1995; **21**: 1238-1247 [PMID: 7737629]

63 **Tsochatzis EA**, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet* 2014; **383**: 1749-1761 [PMID: 24480518 DOI: 10.1016/S0140-6736(14)60121-5]

64 **Evdokimova V**, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. *Cancer Cell* 2009; **15**: 402-415 [PMID: 19411069 DOI: 10.1016/j.ccr.2009.03.017]

65 **Mouneimne G**, Brugge JS. YB-1 translational control of epithelial-mesenchyme transition. *Cancer Cell* 2009; **15**: 357-359 [PMID: 19411064 DOI: 10.1016/j.ccr.2009.04.006]

**P-Reviewer:** Demonacos C, Panda CK **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Germany

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Selected evidence supporting or opposing epithelial-mesenchymal transition during liver fibrogenesis**

|  |  |
| --- | --- |
| **Supporting evidence** | **Ref.**  |
| *In vitro* |  |
| Primary cultured hepatocytes or cholangiocytes with TGF-β stimulation undergo complete EMT.  | [4, 21, 23, 24, 25, 26, 27, 29, 30] |
| *Patients* |  |
| Liver parenchymal cells in patients with advanced chronic liver disease express mesenchymal markers. | [17, 19, 20, 21, 22, 30] |
| **Opposing evidence** |  |
| Techniques based on genetic cell fate mapping of specific cell populations provided convincing evidence that EMT does not occur in fibrotic animal models. | [4, 5, 10] |
| *Clinical observation* |  |
| There is no data showing that parenchymal cells of patients express mesenchymal markers during early stages of fibrosis. |  |
| Parenchymal cells expressing mesenchymal markers are found only in patients with advanced chronic liver disease, *e.g.,* cirrhosis. A cirrhotic liver is not likely to drive remaining parenchymal cells towards a non-essential biological process like EMT. |  |
| No studies indicate that activation of HSC, portal fibroblasts and fibrocytes produce insufficient MFB. |  |
| In the cirrhotic liver, parenchymal cells expressing mesenchymal markers might be caused by high levels of surrounding pro-EMT factors, *e.g.*, TGF-β. |  |